Postdoctoral Fellows

The primary focus of the PNW SPORE is centered on identifying, recruiting and supporting advanced fellows, junior faculty, and established investigators committed to careers in translational prostate cancer research. The entire structure of the CDP is designed to attain this objective. As a corollary to the main deployment of NCI SPORE CDP resources toward faculty-level scientists, we have also developed a strong training program for senior and more junior post-doctoral fellows, believing that supporting a pipeline of well-educated and motivated trainees will pay long-term dividends.

Grant Cycle III

2014-2018

Rohina Rubicz, PhD

Grant Cycle II

2007-2013

Hugh Arnold, PhD (FHCRC)
Tanya Day, PhD (UBC/VGH)
Megan Dann Fesinmeyer, PhD, MPH (FHCRC)
Liesel M. FitzGerald, PhD (FHCRC)
Sean M. Green, PhD (FHCRC)
Boris Hadaschik, PhD (UBC/VGH)
Sarah K. Holt, PhD (FHCRC)
Masafumi Kumano, MD, PhD (UBC)
Francois Lamoureux, PhD (UBC)
Dapei Li, MD, PhD (FHCRC)
Na Li, PhD (UBC)
Jing Meng, PhD (FHCRC)
Hagit Schayek, PhD (UW)
Jonathan Wright, MD (UW)

Rohina Rubicz, PhD Dr. Rubicz earned her MA in Population Genetics in 2001 from the University of Kansas, as well as her PhD in 2007. Before coming to Fred Hutch, Dr. Rubicz was a postdoctoral scientist in the Department of Genetics at Texas Biomedical Research Institute. She joined Dr. Janet Stanford’s Prostate Cancer Research Group in the Division of Public Health Sciences, Department of Epidemiology in 2014 as a Postdoctoral Research Fellow. Currently, Dr. Rubicz’s research focuses on genetic and epigenetic factors that influence prostate cancer recurrence and mortality.

Hugh Arnold, PhD (FHCRC) received his PhD in Molecular and Medical Genetics from Oregon Health and Sciences University in 2007. Dr. Arnold’s research focuses on the mechanisms responsible for the development and sustenance of castration-resistant prostate cancer. He has a broad scientific foundation with expertise in studies of oncogenesis involving the Myc oncoprotein. Dr. Arnold joined the Nelson laboratory in December, 2008. He was recently awarded a fellowship from the FHCRC Chromosome and Metabolism training grant. Dr. Arnold left the program in 2009, for a position as a scientist at GeoSpiza, a biotechnology company focused on developing bioinformatics tools for the analysis of genes and gene expression in diseases that include prostate cancer.
Mentor: Peter Nelson

Tanya Day, PhD (UBC/VGH) is a graduate of Flinders University and Medical Centre in South Australia, where she completed her PhD in the Department of Hematology and Genetic Pathology. Her work on chromosomal inversion response in the prostate after low dose radiation exposure has led to eight publications, five of which as first or last author. She joined Dr. Martin Gleave’s team in late 2006. Her work involves the identification and characterization of expression and biological functions associated with newly identified isoforms and splice variants of human clusterin. Her project involved the identification of functions and regulation of expression of a newly identified, pro-apoptotic, clusterin splice variant. Dr. Day completed her post-doctoral fellowship in December 2008 and she returned to Australia.
Mentor: Martin Gleave

Megan Dann Fesinmeyer, PhD, MPH (FHCRC) received her PhD in Public Health Genetics from the University of Washington in 2007. Dr. Fesinmeyer’s research focuses on prostate cancer, and involves a variety of methodologies including genetic epidemiology, health services research, and population modeling. Dr. Fesinmeyer joined Dr. Stanford’s research group in January 2009. Her work with Dr. Stanford involved identifying associations between variants in prostate cancer candidate genes and risk for prostate cancer, as well as identifying variants and/or haplotypes that may be markers for prostate cancer aggressiveness. Dr. Fesinmeyer left the program in late 2009 and was appointed Staff Scientist in the Program in Biostatistics & Biomathematics at FHCRC.
Mentor: Janet L. Stanford

Liesel M. FitzGerald, PhD (FHCRC) received her PhD in Molecular Genetics from the University of Tasmania, Australia in 2007. The focus of Dr. FitzGerald’s work is in familial genetics and genetic epidemiology with a focus on the field of prostate cancer. She joined the SPORE Career Development Program as a post-doctoral fellow in 2007, and in 2009, she was appointed to Staff Scientist in the Division of Public Health Sciences, working with Drs. Janet Stanford, Elaine Ostrander (NHGRI) and Dan Schaid (Mayo) on the genetic epidemiology of hereditary and sporadic prostate cancer.
Mentor: Janet L. Stanford

Sean M. Green, PhD (FHCRC) received his PhD in Oncological Sciences from the Huntsman Cancer Institute and the University of Utah in May of 2009. His thesis project focused on the analysis of DNA binding by the ETS protein tel(ETV6) under the mentorship of Dr. Barbara Graves. He joined the Nelson laboratory to pursue post-doctoral training under the dual mentorship of Dr. Nelson and Dr. Mostaghel. His research project centers on the development of enzymatic assays for the quantitation of steroid import, synthesis and degradation in prostate carcinoma. He will also evaluate the contribution of germ-line variation in the context of androgen metabolic flux.
Mentor: Peter Nelson and Elahe Mostaghel

Boris Hadaschik, PhD (VGH) joined the Prostate Centre in 2006 as a post-doctoral fellow, working working on preclinical proof-of-principle studies for a new compound called HTI-286 which is being tested both against prostate and bladder cancer. He established and validated an orthotopic bladder cancer model in mice using in vivo bioluminescent imaging and within this model system, evaluated mucoadhesive cytotoxic agents, oncolytic viruses and antisense oligonucleotides as intravesical agents against nonmuscle-invasive bladder cancer, collaborating with Dr. Raymond Andersen (Earth and Ocean Sciences, UBC) and Dr. Helen Burt (Pharmaceutical Sciences, UBC) on some of these projects. Upon completion of his fellowship in 2008, Dr. Hadaschik planned to return to Germany to finish his residency in Urology.
Mentor: Martin Gleave

Sarah K. Holt, PhD (FHCRC) received her PhD in Epidemiology from the University of Washington in Seattle in 2006. The focus of Dr. Holt’s work is in the genetic epidemiology of prostate cancer. She joined the SPORE Career Development program as a post-doctoral fellow in September, 2006. In September, 2008 she moved to the position of staff scientist in the Prostate Cancer Research Group.
Mentor: Janet L. Stanford

Masafumi Kumano, MD, PhD (UBC) was recruited as a post-doctoral fellow in August 2009. He received his Bachelor Degree in Medicine from Wakayama Medical University in Japan, and practiced for two years in the Department of Urology at Kobe University Hospital. He then went on to pursue a doctoral degree in Urology at the Kobe University Graduate School of Medicine. He followed this with a PhD degree at the same university, specializing in the fields of immunology, pathology and molecular cancer biology. Dr. Kumano joined Dr. Gleave’s lab in August 2009, working on two projects: 1) research on the association between Clusterin and Autophagy, and the sub project, 2) is the effect of combination therapy with OGX011 and OGX427.
Mentor: Martin Gleave

Francois Lamoureux, PhD (UBC) received his PhD degree in cellular and molecular biology from Nantes University (France) in the Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumors. His work on novel therapeutic approaches of primary bone tumors by gene transfer has led to ten publications, six of which as first author. He joined Dr. Gleave’s team at the Vancouver Prostate Centre in January 2009, where his work involves the mechanisms of molecular chaperones in prostate cancer progression and the interaction between prostate tumor and bone microenvironment in development of bone metastasis.
Mentor: Martin Gleave

Dapei Li, MD, PhD (FHCRC) received his PhD in Pharmacology from the Medical College of Ohio, and joined the SPORE Career Development program as a post-doctoral fellow working with Dr. Peter Nelson in April of 2006. During 2008/09, he continued work on his SPORE project entitled “Exploiting Prostate Cell Type-Specific Gene Expression Mechanisms for Diagnostic and Therapeutic Applications” focusing on developing panels of markers capable of identifying and isolating cell types within the prostate that exhibit distinct molecular phenotypes. Dr. Li left the program in 2008 and was appointed as a Staff Scientist in the GU Cancer group in the Department of Urology, UW.
Mentor: Peter Nelson

Na Li, PhD (UBC) had medical training in China and completed her PhD in the Department of Pathology at the Juntendo University School of Medicine, Tokyo, Japan. She has a broad research background in genetics, immunology, and molecular biology, which is evident in her 8 publications in peer-reviewed journals (Hum Mol Genet., Arthr. & Rheum., J Immunol., Mol. Ther. etc.). Her most recent work, before she joined the Prostate Centre, was to identify binding partners of human clusterin in prostate cancer (manuscript under preparation). She joined Dr. Martin Gleave’s research team in September, 2008. Her main research topics involved: 1) the mechanism study of retro-translocation of human clusterin under chemo-drug-related ER stress; 2) the identification and characterization of expression and biological functions associated with splice variants of human clusterin.
Mentor: Martin Gleave

Jing Meng, PhD (FHCRC) received her PhD in Molecular and Cellular Biology from the University of Alabama, Department of Biological Sciences, in May of 2003. Her PhD thesis project was focused on understanding the mechanism of mRNA localization that determines cellular fate and pattern formation during oogenesis and early embryonic development. She joined Dr. Robert Braun’s lab as a senior fellow at the University of Washington, School of Medicine where she investigated how androgens influence the formation of the blood-testis barrier. Determined to expand her training in human biology and cancer research, she chose to pursue further post-doctoral research in Dr. Peter Nelson’s laboratory at FHCRC. To date, Dr. Meng has made several novel observations concerning the role of androgens on tight junction proteins in the prostate. She received first prize from the AUA Foundation for this work. Her current research focus centers on the study of androgen metabolic enzyme activity as a mechanism responsible for castration-resistant prostate cancer growth.
Mentor: Peter Nelson

Hagit Schayek, PhD (UW) received her PhD in Molecular Genetics and Biochemistry from Sackler School of Medicine, Tel Aviv University, in 2009. She has extensive experience in molecular and cell biology, and is highly skilled at molecular genetics and biochemistry techniques including PCR, Restriction Analysis, RT-PCR, Nucleic Acid Purification, DNA, RNA, Plasmids Isolation, Genescan, Sequencing, Pyrosequencing, Denaturing Gradient Gel Electrophoresis (DGGE), Protein Truncation Test (PTT), Cell Culture, Western Blot, Immunoprecipitation, Transformation, Transfection and Methylation. During the first two years of her fellowship, she planned to work on AR dimerization of splice variants, transgenic mouse models of AR splice variants, and mechanisms of generation of AR splice variants. Dr. Schayek left the program in 2010 and returned to Israel to pursue a post-doctoral fellowship at Weissmann Research Center.
Mentor: Stephen Plymate

Jonathan Wright, MD, MS (UW/FHCRC) received his medical degree from the University of Washington School of Medicine in 2001. In 2005 he received a Masters in Epidemiology from the University of Washington, School of Public Health. He completed his residency in Urology in 2007 after which he completed a fellowship in Urological Oncology. Dr. Wright joined the SPORE CDP in 2008, and is currently an Assistant Professor at the University of Washington in the Department of Urology and has an appointment as an Affiliate Investigator at the Fred Hutchinson Cancer Research Center.
Mentor: Janet Stanford

Grant Cycle I

2006

  • Zhihong Gong, MPH, PhD (FHCRC)
  • Boris A. Hadaschik, MD (VGH)
  • Sarah K. Holt, PhD (FHCRC)
  • Dapei Li, PhD (FHCRC)
  • Colm Morrissey, PhD (UW)
  • Amina Zoubeidi, PhD (VGH/UBC)

2005

  • Ilir Agalliu, ScD, MD (FHCRC)
  • Zhihong Gong, MPH, PhD (FHCRC)
  • Hooman Hajian, MD, MPH (VGH/UBC)
  • Elahe Mostaghel, MD, PhD (FHCFC/UW)
  • Mototsugu Muramaki, MD (VGH/UBC)
  • Bernie Eigel, MD (VGH/UBC)
  • Amina Zoubeidi, PhD (VGH/UBC)

2004

  • Ilir Agalliu, ScD, MD (FHCRC)
  • Marie Fujino, PhD (FHCRC)
  • Satoko Kojima, MD, PhD (VGH/UBC)
  • Janice Lai, PhD (UW)
  • Elahe Mostaghel, MD, PhD (FHCRC)
  • Mototsugu Muramaki, MD (VGH/UBC)
  • Palma Rocchi, PhD (VGH/UBC)
  • Alan So, MD (VGH/UBC)

2003

  • Claes Bavik, PhD (FHCRC)
  • Janice Lai, PhD (UW)
  • Mauricio Neira, MSc, PhD (VGH/UBC)
  • Palma Rocchi, PhD (VGH/UBC)
  • Alan So, MD (VGH/UBC)
  • Damu Yang, MD, PhD (VGH/UBC)

2002

  • Chen Wei Lin, PhD (FHCRC)
  • Mahesh Keitheri Cheteri, PhD (FHCRC)
  • Martine Roudier, MD, PhD (UW)
  • Alan So, MD (VGH/UBC)
  • Christian Wade, MD (FHCRC)
  • Damu Yang, MD, PhD (VGH/UBC)